ARTICLE
5 December 2017

McDermott's Reverse Engineered Podcast | Five Hot FDA Issues For Life Science Companies (Video)

MW
McDermott Will & Emery

Contributor

McDermott Will & Emery partners with leaders around the world to fuel missions, knock down barriers and shape markets. With more than 1,100 lawyers across several office locations worldwide, our team works seamlessly across practices, industries and geographies to deliver highly effective solutions that propel success.
Health-related technology is growing at an accelerating rate, as is its demand.
United States Food, Drugs, Healthcare, Life Sciences

In Depth

Health-related technology is growing at an accelerating rate, as is its demand. The Food and Drug Administration (FDA), as the gatekeeper tasked with verifying the advertising for health products and the safety and efficacy of such technology, including new mobile platforms, has developed various new regulations in recent years. In this episode, McDermott IP partner Nathan S. Smith welcomes Vernessa Pollard and Veleka Peeples-Dyer, partners in McDermott’s Washington, DC office, to discuss five critical issues that life science companies should consider in dealing with the FDA. The podcast begins with a discussion of recent IP headlines from across the world with Sarah Bro.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More